Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Approves Cabozantinib for Hepatocellular Carcinoma

americanpharmaceuticalreviewJanuary 17, 2019

Tag: FDA , cabozantinib , hepatocellular carcinoma , sorafenib

PharmaSources Customer Service